

Broad-based execution drives further sales and earnings growth

“GSK is delivering strong and sustained performance momentum, with another quarter of double-digit sales and earnings growth. Competitive performance was broadly based but benefitted particularly from the outstanding US launch of Arexvy. Our excellent execution supports an upgrade to our full-year 2023 guidance and we have clear momentum as we look ahead to deliver our 2026 outlooks. GSK’s longer-term outlook also continues to strengthen, with progress in our vaccines pipeline, the development of our ultra long-acting HIV portfolio and significant new prospects in respiratory.”

Emma Walmsley
Chief Executive Officer, GSK



Vaccines
£3.2bn
+33%, +34%
including and excluding COVID-19 solutions

Specialty Medicines
£2.6bn
-1%, +17%
including and excluding COVID-19 solutions, with HIV +15%

General Medicines
£2.3bn
-2%

Adjusted Group operating margin

34.0%

Total EPS

36.1p +>100%

Adjusted EPS

50.4p +17%

Dividend

14p

67
vaccines and specialty medicines in pipeline

17
pipeline assets in phase III / registration

Journalists/media see press release on www.gsk.com for full details on Q3 2023.
Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 17-19, 51 and 52 of the press release.
Product group sales may not add to total sales due to rounding.
References to growth are at constant exchange rates (CER) and for continuing operations unless stated otherwise.